IMGG's revenues decrease 28% for year ended December 31, 2009: StockPreacher.com

StockPreacher.com announces an investment report featuring Imaging3 Inc. (OTCBB:IMGG). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: http://www.stockpreacher.com/n/IMGG

Get our alerts BEFORE the rest of the market. Follow us on Twitter: https://twitter.com/StockPreacher

Imaging3 Inc. (IMGG) is a medical device manufacturer, distributor and third-party service provider of medical equipment, parts, and services to hospitals, surgery centers, research labs, physician offices, and veterinarians. The Company has developed a technology, known as Dominion, which utilizes photo-fluoroscopy to produce three dimensional (3D) medical diagnostic images in real time. Imaging3 is also a remanufacturer of C-arms. The Company offers new, demonstration, remanufactured, refurbished and pre-owned systems in all price ranges from every manufacturer, including OEC, General Electric (GE), ISI, Philips, Siemens, FluoroScan, XiScan and Ziehm. The Company supplies full-size, compact and mini C-arms. The Company was formerly known as Imaging Services Inc. and changed its name to Imaging3, Inc. in August 2002 to position the company for its future direction, away from service and toward providing proprietary medical imaging products. 

Message Board Search for IMGG: http://www.boardcentral.com/boards/IMGG

In the report, the analyst notes:

"IMGG had revenues for the year ended December 31, 2009, of $1,364,892 as compared to $1,755,754 for the year ended December 31, 2008, which represented a 28% decrease. The decrease in sales was attributed directly to a decrease in equipment sales for this period. 

"IMGG, developer of a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time, recently announced that it has submitted the Company's latest response to the FDA."